15-year metastasis-free survival in men on active surveillance in The Netherlands

According to new data reported at the annual meeting of the European Association of Urology in London, active surveillance of men diagnosed with low-risk prostate cancer was not associated with an elevated risk for metastatic disease at 15 years of follow-up. … READ MORE …

Outcomes, side effects, quality of life, and choosing a treatment that works FOR YOU!

Three articles in this week’s Journal of the American Medical Association throw a little more light on issues related to quality of life after diagnosis and treatment for localized prostate cancer … but quite how much light it is difficult to tell. … READ MORE …

For very high-risk patients, EBRT + BT is superior to surgery or EBRT only (redux)

In August last year, Kishan et al. showed a preliminary analysis of oncological outcomes among patients diagnosed with Gleason score 9 and 10 and treated with brachy boost therapy (EBRT + BT), external beam radiation therapy alone (EBRT), or surgery (see this link). … READ MORE …

Wotz goin’ on in Canada? And wotz “True Nth”?

So apparently Prostate Cancer Canada has been working (rather secretively) on a series of projects under the umbrella name of their “True Nth” initiative. But it’s a little difficult to work out quite what is encompassed by this initiative, which has been funded (at least in part) by Movember. … READ MORE …

Ac-225-PSMA-617 apparently extends survival of very late-stage patients: an update

The nuclear medicine group at the University of Heidelberg in Germany recently reported a complete response in two patients treated with Ac-225-PSMA-617 (see this link). … READ MORE …

ADT + sipuleucel-T in treatment of hormone-sensitive prostate cancer

One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease. … READ MORE …

Predicting the future: what Genomic Health isn’t telling us (yet)

A media release issued  yesterday by Genomic Health, Inc., has suggested that the multi-gene Oncotype DX® Genomic Prostate Score™ is a strong predictor of risk for the development of metastasis and prostate cancer death in patients with early-stage prostate cancer. … READ MORE …